BioSenic S.A. : Information on the total number of voting rights and shares
03 Agosto 2023 - 12:00AM
BioSenic S.A. : Information on the total number of voting rights
and shares
REGULATED INFORMATION
Mont-Saint-Guibert, Belgium,
August 2, 2023, 7.00 am CEST –
BIOSENIC (Euronext Brussels and Paris: BIOS), the
innovative company addressing unmet medical needs in in the areas
of innate immunity, inflammation and organ/function repair, today
announces an increase in the total number of voting rights and
shares as a result of the issuance of new shares following the
conversion of convertible bonds. The following information is
published in accordance with article 15 of the Belgian law of 2 May
2007 on the publication of major shareholdings in issuers whose
shares are admitted to trading on regulated market.
Total amount of share capital on July 2, 2023 |
EUR 34 050 669 |
Total number of shares with voting rights on July 2, 2023 |
127 133 857 |
Total number of new shares issued between July 3, 2023 and 01
August 2023 |
4 380 951 |
Total amount of share capital on August 1, 2023 |
EUR 34 300 669 |
Total number of shares with voting rights on August 1, 2023 |
131 514 808 |
Total number of voting rights (denominator) on August 1, 2023 |
131 514 808 |
Total number of attributed warrants |
1 197 554 |
Total number of convertible bonds outstanding |
838 |
Total number of remaining convertible bonds commitments |
18 |
Total number of shares with voting rights that can be issued
following the exercise of the attributed warrants, remaining
convertible bonds commitments and the conversion of the convertible
bonds |
58 860 317 (1) |
(1)
- 1,197,554 shares could be issued in case all 1,197,554
attributed warrants were exercised.
- 285,714 shares could be issued in case all 800 convertible
bonds outstanding, issued in the private placement on May 6, 2020,
were converted into shares based on the predetermined conversion
price of EUR 7.00.
- 57 377 049 shares could be issued in case all 18 convertible
bonds commitments remaining and all 38 convertible bonds
outstanding of the ABO convertible bonds program signed on May 30,
2022 were exercised and converted into shares based on the
conversion price of EUR 0,0488 (95% of the
Volume-Weighted-Averaged-Price of BioSenics’ shares on July 31,
2023).
About BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued from:
(i), the allogeneic cell therapy platform ALLOB and (ii) the
Arsenic TriOxide (ATO) platform. Key target indications for the
platforms include Graft versus Host Disease (GvHD), Systemic lupus
erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial
fractures.
Following the merger in October 2022, BioSenic
combines the strategic positionings and strengths of Medsenic and
Bone Therapeutics. The merger also enables Biosenic to add to its
innovative cell therapy platform and strong IP for tissue repair
protection with an entirely new arsenal of various
anti-inflammatory and anti-autoimmune formulations using the
immunomodulatory properties of ATO/OATO.
BioSenic is based in the Louvain-la-Neuve
Science Park in Mont-Saint-Guibert, Belgium. Further information is
available at http://www.biosenic.com.
About BioSenic technology
platforms
BioSenic’s technology is based on two main
platforms:
- The Arsenic TriOxide (ATO) platform developed by Medsenic. The
immunomodulatory properties of ATO have demonstrated a double basic
effect on cells of the immune system. The first effect is the
increase of the cell oxidative stress in activated B, T or other
cells of the innate/adaptative immune system to the point they will
enter a cell death program (apoptosis) and be eliminated. The
second effect is potent immunomodulatory properties on several
pro-inflammatory cytokines involved in inflammatory or autoimmune
cell pathways, with return to homeostasis. One direct application
is its use in onco-immunology to treat GvHD (Graft-versus-Host
Disease) in its chronic, established stage. GvHD is one of the most
common and clinically significant complications affecting long-term
survival of allogeneic hematopoietic stem cell transplantation
(allo-HSCT). GvHD is primarily mediated by the transplanted immune
cells that can lead to severe multiorgan damage. Medsenic has been
successful in a Phase II trial with its intravenous formulation,
with orphan drug designation status by FDA and EMA. The
company is heading towards an international Phase III confirmatory
study, with its new, IP protected, oral (OATO) formulation.
Moderate to severe forms of Systemic Lupus erythematosus (SLE) is
another selected target, using the same oral formulation. ATO has
shown good safety and significant clinical efficacy on several
affected organs (skin, mucosae and the gastro-intestinal tract) in
an early Phase IIa study.
Systemic Sclerosis is also part of the clinical
pipeline of BioSenic. Preclinical studies on pertinent animal
models are positive. This gives good grounds to launch a Phase II
clinical protocol. This serious chronic disease badly affects skin,
lungs or vascularization, and has no actual current effective
treatment.
- The allogeneic cell and gene therapy platform,
developed by BioSenic with differentiated bone marrow sourced
Mesenchymal Stromal Cells (MSCs), that can be stored at the point
of use in hospitals. Its current investigational medicinal product,
ALLOB, represents a unique, proprietary approach to organ repair
and specifically to bone regeneration, by turning undifferentiated
stromal cells from healthy donors into bone-forming cells on the
site of injury. These cells are produced via a BioSenic's scalable
manufacturing process. Following the CTA (Clinical Trial
Application) approval by regulatory authorities in Europe, BioSenic
had initiated patient recruitment for the Phase IIb clinical trial
with ALLOB in patients with difficult tibial fractures, using its
optimized production process. ALLOB has been evaluated in a
randomized, double-blind, placebo-controlled Phase IIb study in
patients with high-risk tibial fractures, using its optimized
production process, after a successful first safety and efficacy
study (Phase 1/2a) on fractured long bones, with late delayed
union. The patient recruitment has been halted late February 2023
with 57 patients and the new rules permitted for statistical
analysis allowed BioSenic to get the main results of this trial
much earlier than anticipated in the original protocol. In June
2023, BioSenic decided to suspend its interventional trial on
fracture healing using ALLOB, following negative results obtained
for the primary endpoint in the exploratory Phase IIb clinical
trial with ALLOB, focused on safety and treatment timing efficacy
(choice between early or late treatment).
In addition, BioSenic is working on a
next-generation, off-the-shelf, enhanced viscosupplement, JTA, for
knee osteoarthritis (OA), made of a unique combination of mammalian
plasma proteins, derivatives of hyaluronic acid (a natural
component of synovial fluid in the knee) and a third active
component. JTA or some derivatives intend to provide added
lubrication and protection to the cartilage of the arthritic joint
and to alleviate osteoarthritic pain (OA) and inflammation. In
March 2023, after the clinical identification of distinct OA
subtypes, BioSenic delivered a new post-hoc analysis of its Phase
III JTA-004 trial on knee OA, demonstrating positive action on the
most severely affected patient sub-population. This new post-hoc
analysis drastically changes the therapeutic profile of the
combined components and allows for better patient targeting in
future clinical developments. The company, which does not intend to
allocate R&D resources to support the clinical development of
JTA-004, will focus its R&D and clinical activities on an
accelerated development of its autoimmune (ATO/OATO) platform.
For further information, please
contact:
BioSenic SAFrançois Rieger, PhD,
Chief Executive OfficerTel: +33 (0)671 73 31
59investorrelations@biosenic.com
International Media Enquiries:IB
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei
ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11
22ggasparetto@actifin.fr
Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect the Company or, as appropriate, the Company
directors’ current expectations and projections about future
events. By their nature, forward-looking statements involve a
number of risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated
development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, the Company expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biosenic (EU:BIOS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Biosenic (EU:BIOS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024